Logo image of GLYC

GLYCOMIMETICS INC (GLYC) Stock Fundamental Analysis

NASDAQ:GLYC - Nasdaq - US38000Q1022 - Common Stock - Currency: USD

0.2378  -0.01 (-4.11%)

Fundamental Rating

2

GLYC gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 561 industry peers in the Biotechnology industry. While GLYC seems to be doing ok healthwise, there are quite some concerns on its profitability. GLYC has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

GLYC had negative earnings in the past year.
GLYC had a negative operating cash flow in the past year.
GLYC had negative earnings in each of the past 5 years.
GLYC had a negative operating cash flow in each of the past 5 years.
GLYC Yearly Net Income VS EBIT VS OCF VS FCFGLYC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

With a Return On Assets value of -341.52%, GLYC is not doing good in the industry: 95.54% of the companies in the same industry are doing better.
Looking at the Return On Equity, with a value of -712.87%, GLYC is doing worse than 82.35% of the companies in the same industry.
Industry RankSector Rank
ROA -341.52%
ROE -712.87%
ROIC N/A
ROA(3y)-171.03%
ROA(5y)-123.21%
ROE(3y)-305.92%
ROE(5y)-207.06%
ROIC(3y)N/A
ROIC(5y)N/A
GLYC Yearly ROA, ROE, ROICGLYC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600

1.3 Margins

GLYC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GLYC Yearly Profit, Operating, Gross MarginsGLYC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100K -200K -300K

More info and screens

5

2. Health

2.1 Basic Checks

GLYC does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, GLYC has about the same amount of shares outstanding.
The number of shares outstanding for GLYC has been increased compared to 5 years ago.
GLYC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
GLYC Yearly Shares OutstandingGLYC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
GLYC Yearly Total Debt VS Total AssetsGLYC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

GLYC has an Altman-Z score of -69.84. This is a bad value and indicates that GLYC is not financially healthy and even has some risk of bankruptcy.
GLYC has a worse Altman-Z score (-69.84) than 95.90% of its industry peers.
There is no outstanding debt for GLYC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -69.84
ROIC/WACCN/A
WACC10.06%
GLYC Yearly LT Debt VS Equity VS FCFGLYC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M 200M

2.3 Liquidity

GLYC has a Current Ratio of 1.92. This is a normal value and indicates that GLYC is financially healthy and should not expect problems in meeting its short term obligations.
GLYC's Current ratio of 1.92 is on the low side compared to the rest of the industry. GLYC is outperformed by 77.01% of its industry peers.
A Quick Ratio of 1.92 indicates that GLYC should not have too much problems paying its short term obligations.
GLYC's Quick ratio of 1.92 is on the low side compared to the rest of the industry. GLYC is outperformed by 75.40% of its industry peers.
Industry RankSector Rank
Current Ratio 1.92
Quick Ratio 1.92
GLYC Yearly Current Assets VS Current LiabilitesGLYC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for GLYC have decreased by -1.14% in the last year.
GLYC shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)-1.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20.57%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, GLYC will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.91% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y96.71%
EPS Next 2Y39.66%
EPS Next 3Y24.95%
EPS Next 5Y13.91%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GLYC Yearly Revenue VS EstimatesGLYC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2020 2021 2022 2023 2029 2030 2031 2032 50M 100M 150M 200M 250M
GLYC Yearly EPS VS EstimatesGLYC Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 -0.5 -1 -1.5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

GLYC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GLYC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GLYC Price Earnings VS Forward Price EarningsGLYC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GLYC Per share dataGLYC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4

4.3 Compensation for Growth

GLYC's earnings are expected to grow with 24.95% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.66%
EPS Next 3Y24.95%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for GLYC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GLYCOMIMETICS INC

NASDAQ:GLYC (5/23/2025, 11:41:39 AM)

0.2378

-0.01 (-4.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-07 2025-05-07
Earnings (Next)08-06 2025-08-06
Inst Owners47.17%
Inst Owner Change1.28%
Ins Owners2.71%
Ins Owner Change0%
Market Cap15.34M
Analysts82.86
Price Target1.02 (328.93%)
Short Float %2.92%
Short Ratio5.14
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)95.4%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.89
P/tB 2.89
EV/EBITDA N/A
EPS(TTM)-0.59
EYN/A
EPS(NY)-0.02
Fwd EYN/A
FCF(TTM)-0.48
FCFYN/A
OCF(TTM)-0.48
OCFYN/A
SpS0
BVpS0.08
TBVpS0.08
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -341.52%
ROE -712.87%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-171.03%
ROA(5y)-123.21%
ROE(3y)-305.92%
ROE(5y)-207.06%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 28.41%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.92
Quick Ratio 1.92
Altman-Z -69.84
F-Score2
WACC10.06%
ROIC/WACCN/A
Cap/Depr(3y)26.82%
Cap/Depr(5y)22.05%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20.57%
EPS Next Y96.71%
EPS Next 2Y39.66%
EPS Next 3Y24.95%
EPS Next 5Y13.91%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y17.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y10.87%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y10.84%
OCF growth 3YN/A
OCF growth 5YN/A